Broadening the Efficacy of Cancer Immunotherapies

扩大癌症免疫疗法的功效

• 批准号: nhmrc : GNT1159655
• 负责人: A/Pr Michele Teng
• 金额: $ 48.34万
• 依托单位国家: 澳大利亚
• 项目类别: Career Development Fellowships
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/broadening-efficacy-cancer-immunotherapies/1349304
• 关键词: Broadening; Efficacy; Cancer; Immunotherapies

Over the past 5 years, antibodies targeting immunomodulatory receptors such as Ipilimumab, Nivolumab/Pembrolizumab have been revolutionary in causing long term tumor regression and disease free survival in advanced cancers. My vision is to increase the proportion of cancer patients that will respond to immunotherapy by exploring novel pathways and combinations and optimizing their scheduling and assessing their safety in mouse models to allow their rapid translation into the clinic.

在过去的 5 年里，针对免疫调节受体的抗体（例如 Ipilimumab、Nivolumab/Pembrolizumab）在导致晚期癌症的长期肿瘤消退和无病生存方面取得了革命性的进展。我的愿景是通过探索新的途径和组合、优化其治疗安排并评估其在小鼠模型中的安全性，以提高对免疫治疗有反应的癌症患者的比例，从而使其能够快速转化为临床。